Current stock page

Stock Analysis

Merck & Co., Inc. (MRK) Stock Analysis

Merck & Co., Inc. (MRK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

MRK Stock Analysis Summary

Merck & Co., Inc. (MRK) currently has an AIQ Score of 47/100, indicating a neutral setup. Momentum is the strongest factor at 77/100. Value is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 2, 2026 · Market-close data

MRK at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$151.64
AIQ Score47/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$370.32B
P/E Ratio119
Forward P/E
EPS-$0.54
Revenue TTM$16.61B
Dividend Yield0.01%
Beta0.21
Volume8.97M
52-week range$77.58-$156.92
RSI 1467.77
50-Day SMA$133.46
200-Day SMA$117.82
Analyst Price Target$148.82
Next EarningsOct 29, 2026
As of Sep 2, 2026 · Market close

MRK

Overview
Merck & Co., Inc.
Healthcare· Drug Manufacturers - General
AIQ Score
NeutralAIQ Edge 4/10
Low Priority
In Line With Peers
Score data as of Sep 2, 2026
Last price
$151.64
+$1.78 (+1.19%)
Latest market quote
Momentum77
Value27
Quality47
Risk Resilience36
Sentiment50
View financial data

MRK Stock Analysis Summary

Merck & Co., Inc. (MRK) currently has an AIQ Score of 47/100, indicating a neutral setup. Momentum is the strongest factor at 77/100. Value is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 2, 2026 · Market-close data
AIQ Composite Posture: Mixed

In a neutral regime, MRK has AIQ Score of 47/100 with Momentum base of 77/100 and fading Value at 27/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (77/100) leads while Value (27/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.19% stock move · MRK classified in Drug Manufacturers - General.

Current Evidence

NeutralMRK is in a neutral AIQ regime; Momentum is the strongest visible factor at 77/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is MRK Bullish or Bearish Right Now?

MRK currently has a neutral overall setup. Momentum is the strongest factor at 77/100, while Value is weakest at 27/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 77/100.
  • - Price is +13.62% above its 50-day SMA.
  • - Technical consensus has more buy votes than sell votes (37 vs 2).
Bear Case
  • - Value is the current constraint at 27/100.
  • - Risk Resilience is weak at 36/100.
  • - Analyst target implies -1.86% downside from the latest quote.

Current Consensus

MRK's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 6 neutral, and 2 sell votes. MRK's 14-day RSI is 67.77, which places the stock in a constructive momentum range. MRK's beta is 0.21, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in MRK?

Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.

AIQ Score
47/100
Momentum
77/100
Quality
47/100
Risk
36/100

What Would Change the MRK Outlook?

The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

MRK Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

MRK Fundamentals

MRK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$16.61B
Net income
-$1.34B
Free cash flow
$4.48B
View full MRK fundamental analysis

MRK Technical Analysis

MRK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
67.77
Price vs SMA-50
+13.62%
View full MRK technical analysis

MRK Stock Catalysts

Track MRK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Oct 29, 2026
Analyst target
$148.82
News items
1
View MRK earnings and stock catalysts

MRK Dividend Analysis

MRK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
2.22%
Annual dividend
$3.36
Payout ratio
View MRK dividend history and analysis

MRK Financial Data

MRK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$16.61B
EPS
-$0.54
Periods
8
View MRK financials

MRK Risk Analysis

MRK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.21
Risk score
36/100
AIQ Score
47/100
View MRK risk analysis

MRK Stock News

MRK stock news, market tone, recent headlines, and catalyst context.

News items
1
Updated
Sep 3, 2026
Sentiment
50/100
Read MRK stock news

Popular MRK Comparisons

How MRK scores against the names it is most often compared with.

About the AIQ Score

Methodology for the current stock evidence.

As of Sep 2, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a MRK stock return scenario

Open the stock profit calculator with ticker context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Sep 3, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
119
As of Sep 2, 2026
Revenue growth
1.97%
Gross margin
75.38%
Current debt / equity
1.29
Latest quarterly evidence

Latest period Jun 30, 2026.

Review fundamentals
Quarter revenue
$16.61B
Quarter net income
-$1.34B
Quarter free cash flow
$4.48B

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
67.77
MACD
5.83

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
36/100
Beta
0.21
Annual volatility
30.63%
Max drawdown
-11.90%
Recent News
See all news
Sentiment —
No recent news found for MRK

Merck & Co., Inc. (MRK) Stock Analysis

Snapshot summary of AIQ score, trend, and risk context.

Merck & Co., Inc. has an AIQ Score of 47/100 in a Neutral regime. Momentum is strongest at 77/100.

The main conflict is that momentum leads at 77/100 while value lags at 27/100. Review the supporting factors together before drawing a conclusion from any single score.

Beta is 0.21, below market sensitivity. Current price is $151.64 and RSI (14) is 67.8.

Regime Context
MRK is in a Neutral AIQ regime with score 47/100.
Signal Conflict
The primary conflict is that momentum leads at 77/100 while value lags at 27/100.
Factor Evidence
Momentum 77/100 · Value 27/100 · Quality 47/100 · Risk 36/100 · Sentiment 50/100
Persistence
Current snapshot evidence is shown; historical persistence remains in AIQ Pro.
Factor strength
Pass
Momentum is the strongest factor at 77/100.
Timing
Pass
Momentum is 77/100 and RSI (14) is 67.8.
Regime fit
Wait
MRK is in a Neutral regime at 47/100.
Risk control
Fail
Risk factor is 36/100 with beta 0.21 and annual volatility 30.63%.
Conflict
Wait
Current conflict: momentum leads at 77/100 while value lags at 27/100.
AIQ Score47/100
Price$151.64
Beta0.21
RSI (14)67.8

Compare with Similar Stocks

See how MRK stacks up against its peers
Compare Stocks

Portfolio Implication

MRK currently shows elevated risk sensitivity. Beta is 0.21, below market sensitivity.

MRK Stock FAQ

What is MRK stock price today?

Merck & Co., Inc.'s current stock price is $151.64. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is MRK bullish or bearish right now?

MRK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is MRK's market cap?

MRK's market cap is $370.32B based on the latest completed market-close snapshot from Sep 2, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is MRK's current P/E ratio?

MRK's current P/E ratio is 119 based on the latest completed market-close snapshot from Sep 2, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is MRK's RSI?

MRK's 14-day RSI is 67.77 based on the latest completed market-close snapshot from Sep 2, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is MRK above its 50-day and 200-day moving averages?

MRK is 13.62% from its 50-day SMA and 28.70% from its 200-day SMA based on the latest completed market-close snapshot from Sep 2, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is MRK's next earnings date?

MRK's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does MRK pay a dividend?

MRK's dividend yield is 0.01% based on the latest completed market-close snapshot from Sep 2, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.